{"id":"W2883739562","doi":"10.1016/s2468-1253(18)30233-4","title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","year":2018,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":156,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Dr. Falk Pharma; Celltrion; Boehringer Ingelheim; Gilead Sciences; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Crohn's disease; Internal medicine; Placebo; Clinical trial; Gastroenterology; Adverse effect; Clinical endpoint; Severity of illness; Maintenance therapy; Surgery; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000394029,0.0003975753,0.0005519695,0.0001089886,0.0002598498,0.00006023254,0.001189665,0.0001587878,0.00004012953],"category_scores_gemma":[0.00003362793,0.0003107329,0.00003421629,0.0001164278,0.0003854161,0.00002709242,0.0008792857,0.0002564596,0.00005492199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005383838,"about_ca_system_score_gemma":0.0001339918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006332566,"about_ca_topic_score_gemma":0.006852535,"domain_scores_codex":[0.9963962,0.0009178612,0.0004199794,0.001092951,0.0001970195,0.0009759556],"domain_scores_gemma":[0.9976708,0.00001170919,0.0001704284,0.00155004,0.0002633678,0.0003336076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05581329,0.001705603,0.9384586,0.000008395321,0.0001003263,0.0004384915,0.0001384059,0.00008886836,0.0003311358,0.00001258211,0.002619103,0.0002851533],"study_design_scores_gemma":[0.01301617,0.005822432,0.9796505,0.00001206014,0.00006327213,0.00002480604,0.0000504122,0.0004786731,0.00001754317,0.00006382455,0.0005595417,0.0002407863],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970461,0.0000208231,0.0003857254,0.0004106196,0.0002933787,0.0016612,0.00008216764,0.00003282947,0.00006717032],"genre_scores_gemma":[0.9916745,0.000003696424,0.0003162048,0.007096161,0.000319518,0.0002991861,0.0001623656,0.00006175749,0.00006657535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04279711,"threshold_uncertainty_score":0.9999345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01730062530458918,"score_gpt":0.2744220794148416,"score_spread":0.2571214541102524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}